- ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
- ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
- Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
- ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
- ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
- ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
- ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
- ResMed Secures Significant Victory in Patent Fight Against New York University
- Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
More ▼
Key statistics
As of last trade, Resmed Inc (RME:STU) traded at 168.05, 32.43% above the 52 week low of 126.90 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 167.75 |
---|---|
High | 168.05 |
Low | 167.75 |
Bid | 163.15 |
Offer | 175.55 |
Previous close | 166.50 |
Average volume | 36.00 |
---|---|
Shares outstanding | 147.09m |
Free float | 145.88m |
P/E (TTM) | 29.88 |
Market cap | 26.53bn USD |
EPS (TTM) | 6.04 USD |
Annual div (ADY) | 1.78 EUR |
---|---|
Annual div yield (ADY) | 1.06% |
Div ex-date | Feb 07 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of Apr 22 2024.
More ▼